Contenu

x

Moteur de recherche interne

Grenoble Excellence in neurodegeneration Grenoble Excellence in neurodegeneration

Accueil > Publications > Publications du GIN et du CHU

Accéder au plan complet du site

Publications du GIN & du CHUG

  • Becerril-Ortega J, Bordji K, Fréret T, Rush T, Buisson A. 2014. Iron overload accelerates neuronal amyloid-β production and cognitive impairment in transgenic mice model of Alzheimer's disease. Neurobiol Aging. 35 (10): 2288-301. (IF 6.63)

  • Bordji K, Becerril-Ortega J, Nicole O, Buisson A. 2010. Activation of extrasynaptic, but not synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and increases amyloid-ß production. J Neurosci. 30(47): 15927-42. (IF 6.7)

  • Carnicella S, Drui G, Boulet S, Carcenac C, Favier M, Duran T, Savasta M. 2014. Implication of dopamine D3 receptor activation in the reversion of Parkinson's disease-related motivational deficits. Transl Psychiatry. 17; 4: e401. (FI 4.36)

  • Chassefeyre, R.* José Martínez-Hernández, J.*, Bertaso, F., Bouquier, N., Blot, B. , Laporte, M., Fraboulet, S., Couté, Y., Devoy , A., Isaacs, A., Pernet-Gallay, K., Sadoul, R.* Fagni, L., Goldberg, Y.* 2015. Regulation of post-synaptic function by the dementia-related ESCRT-III subunit CHMP2BJ. Neurosci, 35(7): 3155-3173. (IF 6.7)
  • Coquery N., Francois O., Lemasson B., Debacker C., Farion R., Rémy C, Barbier E.L. Microvascular MRI and unsupervised clustering yields histology-like maps in two rat models of glioma. Journal of Cerebral Blood Flow and Metabolism, 34(8):1354-62, 2014.

  • Daoust A. , Bohic S., Saoudi Y., Debacker C., Gory-Fauré S., Andrieux A., Barbier E.L, Deloulme J.C. Neuronal transport defects of the MAP6 KO mouse – a model of schizophrenia – and alleviation by Epothilone D treatment, as observed using MEMRI. Neuroimage. 96C:133-142, 2014.

  • Davies KM*, Bohic S*, Carmona A, Ortega R, Cottam V, Hare DJ, Finberg JP, Reyes S, Halliday GM, Mercer JF, Double KL. 2014. Copper pathology in vulnerable brain regions in Parkinson's disease. Neurobiol Aging. 858-66. *equal contribution (IF 6.63)

  • Dolei, A., J.A. Garson, G. Arru, M. Clerici, R. Germi, P.N. Marche, and H. Perron. 2014. Multiple sclerosis-associated retrovirus and related human endogenous retrovirus-W in patients with multiple sclerosis. J Neuroimmunol 266: 87-88. (IF 2.78)

  • Drui G, Carnicella S, Carcenac C, Favier M, Bertrand A, Boulet S, Savasta M. 2014. Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson's disease. Mol Psychiatry. 19(3): 358-67. (IF 15.15)

  • Dufour E., Moni L.,Bonnat L., Chierici S., and Garcia J. 2014. Clikable’ 2,5-diketopiperazines as scaffolds for ligation of biomolecules: application in Aβ inhibitors. Organic and Biomolecular chemistry. 12, 4964-4974. (IF 3.4)

  • Duperray, A., D. Barbe, G. Raguenez, B.B. Weksler, I.A. Romero, P.O. Couraud, H. Perron, and P.Marche. 2015. Inflammatory response of endothelial cells to a human endogenous retrovirusassociated with multiple sclerosis is mediated by TLR4. Int Immunology, in press. (IF 3.3)

  • El Massri N, Johnstone DM, Peoples CL, Moro C, Reinhart F, Torres N, Stone J, Benabid AL, Mitrofanis J. 2015. The effect of different doses of near infrared light on dopaminergic cell survival and gliosis in MPTP-treated mice. Int J Neurosci. Epub. Jan 7. (IF 2.64)

  • Elie A, Prezel E, Guérin C, Denarier E, Ramirez-Rios S, Serre L, Andrieux A, Fourest-Lieuvin A, Blanchoin L, Arnal I. 2015. Tau co-organizes dynamic microtubule and actin networks. Sci Rep., 5, 9964. (IF 5.07)

  • Favier M, Duran T, Carcenac C, Drui G, Savasta M, Carnicella S. 2014. Pramipexole reverses Parkinson's disease-related motivational deficits in rats. Mov Disord. 29(7): 912-20. (IF 4.48)

  • Frandemiche ML, De Seranno S, Rush T, Borel E, Elie A, Arnal I, Lanté F, Buisson A. 2014. Activity-dependent tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-beta oligomers. J Neurosci. 34(17): 6084-97. (IF 6.7)

  • Garin D, Virgone-Carlotta A, Gözel B, Oukhatar F, Perret P, Marti-Battle D, Touret M, Millet P, Dubois-Dauphin M, Meyronet D, Streichenberger N, Laferla FM, Demeunynck M, Chierici S, Sallanon MM, Ghezzi C. 2015. COB231 targets amyloid plaques in post-mortem human brain tissue and in an Alzheimer mouse model. J Neurochem., 132, 609-618. (IF 4.33)

  • Godin JD, Colombo K, Molina-Calavita M, Keryer G, Zala D, Charrin BC, Dietrich P, Volvert ML, Guillemot F, Dragatsis I, Bellaiche Y, Saudou F, Nguyen L, Humbert S. 2010. Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis. Neuron. 67(3): 392-406. (IF 16.48)

  • Keryer G, Pineda JR, Liot G, Kim J, Dietrich P, Benstaali C, Smith K, Cordelières FP, Spassky N, Ferrante RJ, Dragatsis I, Saudou F. 2011. Ciliogenesis is regulated by a huntingtin-HAP1-PCM1 pathway and is altered in Huntington disease. J Clin Invest. 121(11): 4372-82. (IF 13.76)

  • Moreira Sousa C, McGuire JR, Thion MS, Gentien D, de la Grange P, Tezenas du Montcel S, Vincent-Salomon A, Durr A, Humbert S. 2013. The Huntington disease protein accelerates breast tumour development and metastasis through ErbB2/HER2 signalling. EMBO Mol Med. 5(2): 309-25. (IF 8.24)

  • Moro, C., Massri, N.E., Torres, N., Ratel, D., De Jaeger, X., Chabrol, C., Perraut, F., Bourgerette, A., Berger, M., Purushothuman, S., Johnstone, D., Stone, J., Mitrofanis, J., and Benabid, A-L. 2014. Photobiomodulation inside the brain: a novel method of applying near-infrared light intracranially and its impact on dopaminergic cell survival in MPTP-treated mice. J. Neurosurg. 120: 670–683. (IF2.73)

  • Moro, C., Torres, N., El Massri, N., Ratel, D., Johnstone, D.M., Stone, J., Mitrofanis, J., and Benabid, A-L. 2013. Photobiomodulation preserves behaviour and midbrain dopaminergic cells from MPTP toxicity: evidence from two mouse strains. BMC Neurosci 14: 40. (IF 2.84)

  • Ouberai M., Dolphin G.T., Dumy P., and Garcia J., 2011. Amyloidogenesis highlighted by designed peptides forming supramolecular self-assemblies. Chemical Science, 2, 1293-1300. (IF 8.6)

  • Ouberai M., Dumy P., Chierici S., and Garcia J., 2009. Synthesis and Biological Evaluation of Clicked Curcumin and Clicked KLVFFA Conjugates as Inhibitors beta-Amyloid Fibril Formation. Bioconjugate Chemistry, 20, 2123-2132. (IF 4.8)

  • Perron, H., A. Lang, F. Curtin, P. Marche, P. Morand, and J-L. Touraine. 2012. First specific therapeutic approach targeting a pathogenic Human Endogenous Retrovirus Protein in Multiple Sclerosis. J Neurovirology. 84-85. (IF 3.32)

  • Perron, H., E. Jouvin-Marche, M. Michel, A. Ounanian-Paraz, S. Camelo, A. Dumon, C. Jolivet-Reynaud, F. Marcel, Y. Souillet, E. Borel, L. Gebuhrer, L. Santoro, S. Marcel, J. Seigneurin, P. Marche, and M. Lafon. 2001. Multiple sclerosis retrovirus particles and recombinant envelope trigger an abnormal immune response in vitro, by inducing polyclonal V beta 16 T-lymphocyte activation. Virology. 287: 321-332. (IF 3.2)

  • Rolland M, Carcenac C, Overton PG, Savasta M, Coizet V. 2013. Enhanced visual responses in the superior colliculus and subthalamic nucleus in an animal model of Parkinson's disease. Neuroscience. 252: 277-88. (IF 3.45)

  • Saresella, M., A. Rolland, I. Marventano, R. Cavarretta, D. Caputo, P. Marche, H. Perron, and M. Clerici. 2009. Multiple sclerosis-associated retroviral agent (MSRV)-stimulated cytokine production in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis 15: 443-447. (IF 4.86)

  • Zala D, Hinckelmann MV, Yu H, Lyra da Cunha MM, Liot G, Cordelières FP, Marco S, Saudou F. 2013. Vesicular glycolysis provides on-board energy for fast axonal transport. Cell. 152(3): 479-91. (IF 33.11)

  • Benis D, David O, Lachaux JP, et al. 2014. Subthalamic nucleus activity dissociates proactive and reactive inhibition in patients with Parkinson’s disease. Neuroimage. 91: 273-81. (IF 5.6)

  • Cantin S, Villien M, Moreaud O, Tropres I, Keignart S, Chipon E, Le Bas JF, Warnking J, Krainik A. 2011. Impaired cerebral vasoreactivity to CO2 in Alzheimer's disease using BOLD fMRI Neuroimage. 58 (2):579-87. (IF 5.6)

  • Castrioto, A, C Piscicelli, D Pérennou, P Krack, B Debu. 2014. The Pathogenesis of Pisa Syndrome in Parkinson's Disease. Movement disorders; 29: 1100-1107. (IF 5.6)

  • Castrioto A, Lhommée E, Moro E, Krack P. 2014. Mood and behavioural effects of subthalamic stimulation in Parkinson’s disease. Lancet Neurol.13: 287-305. (IF 21.82)

  • Cohen M, Maillart E, Tourbah A, … Casez O, et al, for the Club Francophone de la Sclérose en Plaques Investigators. 2014. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. JAMA Neurol. 71: 436-41. (IF 7)

  • Hinsinger G, Galéotti N, Nabholz N, … Casez O, et al. 2015. Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. Multiple Sclerosis Feb 19. pii: 1352458514561906. (IF 4.8)

  • Klein-Koerkamp Y., Heckemann R.A., Ramdeen K., Moreaud O., Keignart S., Krainik A., Hammers A., Baciu M., Hot P. 2014. Is There Better than the Hippocampus? A Look into Amygdalar Atrophy in Early Alzheimer’s Disease. Curr Alzheimer Res. 11: 239-252. (IF 4.95)

  • Krack P, Hariz MI. 2013. Deepbrain stimulation in Parkinson’sdisease: reconciliation of evidencebasedmedicinewithclinical practice.Lancet Neurol 12: 25-6. (IF 21.82)

  • Krack, P; Batir, A; Van Blercom, N , Chabardes S, Fraix V, Ardouin C, Koudsie A, Dowsey-Limousin P, Benazzouz A, Le Bas JF, Benabid AL, Pollak P. 2003. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med. 349 (20): 1925-34. (Cited: 884 times Average: 73.67). (IF 54.42)

  • Moro E. Parkinson disease: Let’s listen to patients with PD after deep brain stimulation. 2014. Nat Rev Neurol. 10: 550-2. (IF 14.10)

  • Nicolas G, Pottier C, Charbonnier C, …Sauvée M, et al, for theFrench IBGC Study Group. 2013. Phenotypicspectrum of probable and genetically-confirmed idiopathic basal ganglia calcification. Brain. 136: 3395-3407. (IF 10,2)

  • Nosko D, Ferraye MU, Fraix V, Goetz L, Chabardès S, Pollak P, Debû B. 2014. Low-frequency versus high-frequency stimulation of the pedunculopontine nucleus area in Parkinson’s disease: a randomized controlled trial.J Neurol Neurosurg Psychiatry. Sep 2. (IF 5.58)

  • Perret-Liaudet A, Pelpel M, Tholance Y, Dumont B, Vanderstichele H, Zorzi W, Elmoualij B, Schraen S, Moreaud O, et al. 2012. Risk of Alzheimer’s disease biological misdiagnosis linked to cerebrospinal collection tubes. J Alzheimer D. 31: 13-20. (IF 3,6)

  • Pinto S, Ferraye M, Espesser R, et al. 2014. Stimulation of the pedunculopontine nucleus area in Parkinson’s disease: effects on speech and intelligibility. Brain. 137: 2759-72. (IF 10,2)

  • Rousseaux, D Pérennou. 2004. Comfort care intake in severely disabled multiple sclerosis patients. J Neurol Sci. 222: 39-48. (IF 2.24)

  • Sauvée M, DidierLaurent G, Latarche C, Escanyé MC, Olivier JL, Malaplate-Armand C. 2014. Additional use of Aβ₄₂/Aβ₄₀ ratio withcerebrospinalfluidbiomarkers P-tau and Aβ₄₂increases the level of evidence of Alzheimer'sdiseasepathophysiologicalprocess in routine practice. J Alzheimer D. 41: 377-386. (IF 3,6)

  • Schuepbach WM, Rau J, Knudsen K, Volkmann J, Krack P, et al, for the EARLYSTIM Study Group. 2013. Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med. 368: 610-22. (IF 54.42)

  • Thobois S, Lhommée E, Klinger H, …Krack P. 2013. Parkinsonian apathy responds to dopaminergicstimulation of D2/D3 receptors with piribedil. Brain. 136: 1568-77. (IF 10,2)


Mise à jour le 7 avril 2016

Membres
Associés renforcés
Associés simples